CAS 1413431-07-8

Ivacaftor (4-tertbutyl-d9) (Major)

Controlled Product

CAS: 1413431-07-8

Formula: C₂₄H₁₉D₉N₂O₃

Color and Shape: Neat

Molecular weight: 401.55

Ref: TR-I940603

Ivacaftor (4-tertbutyl-d9) (major)

CAS: 1413431-07-8

Ivacaftor is a drug substance with the molecular formula C17H20Cl2O3, a monocarboxylic acid amide. Ivacaftor is indicated as a treatment for cystic fibrosis (CF) in patients age 12 years and older who have one of the following mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or R117C. Ivacaftor binds to and activates the CFTR protein by increasing its stability and function. The carboxyl terminal domain of CFTR is required for interaction with ivacaftor. Ivacaftor also potentiates the activity of chromenes such as ivacaftor (4-tertbutyl-d9) and other cftr potentiators such as VX-770. These compounds are being studied in cancer treatment because they may be able to

Formula: C₂₄H₂₈N₂O₃

Purity: Min. 95%

Molecular weight: 401.5 g/mol

Ref: 3D-NGC43107

Ivacaftor-D9

CAS: 1413431-07-8

CTP-656, a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator, is used potentially for the treatment of cystic fibrosis.

Formula: C₂₄H₁₉D₉N₂O₃

Color and Shape: Solid

Molecular weight: 401.55

Ref: TM-T27098